Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The choice between them for glycemic control alone would likely favor tirzepatide simply because it is available and proven, while retatrutide remains investigational
Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update
For research reference only
What the Numbers Show Average weight loss by timepoint: Week 12: 8.7% total body weight (19 pounds for 220-pound person) Week 24: 17.3% total body weight (38 pounds for 220-pound person) Week 36: 21.1% total body weight (46 pounds for 220-pound person) Week 48: 24.2% total body weight (53 pounds for 220-pound person) Data from Phase 2 clinical trial, 12mg dose cohort
#62 Bicep training is on point
c represents the number of reports without target drug exposure but with target AEs
US$ 22.53
US$ 22.31
US$ 28.37
